{"id":829380,"date":"2025-03-25T08:08:40","date_gmt":"2025-03-25T12:08:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/"},"modified":"2025-03-25T08:08:40","modified_gmt":"2025-03-25T12:08:40","slug":"mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/","title":{"rendered":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET"},"content":{"rendered":"

\nLuke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
\n<\/h2>\n
\n

RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the current treatment paradigm.<\/p>\n\n\n\n\n\n
\n
\n
\n Tuesday, April 1st<\/sup> @ 8:00 a.m. ET<\/u>
\n <\/em>
\n <\/strong>\n <\/td>\n<\/tr>\n
Domestic:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1-877-704-4453\u00a0<\/td>\n<\/tr>\n
International: <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1-201-389-0920<\/td>\n<\/tr>\n
Webcast:<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Link<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

A live webcast of the conference call may also be found on the \u201cNews & Events<\/a>\u201d page in the Investor Relations section of the Mineralys Therapeutics website.<\/p>\n

\n About Mineralys Therapeutics
<\/strong>Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https:\/\/mineralystx.com<\/a>. Follow Mineralys on LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\n Contact:
<\/strong>
\n Investor Relations
<\/strong>
\n investorrelations@mineralystx.com<\/a>\n <\/p>\n

\n Media Relations
<\/strong>Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the … <\/p>\n

Continue reading “Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829380","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the … Continue reading "Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T12:08:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET\",\"datePublished\":\"2025-03-25T12:08:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/\"},\"wordCount\":288,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/\",\"name\":\"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==\",\"datePublished\":\"2025-03-25T12:08:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/","og_locale":"en_US","og_type":"article","og_title":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - Market Newsdesk","og_description":"Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the … Continue reading \"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T12:08:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET","datePublished":"2025-03-25T12:08:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/"},"wordCount":288,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/","name":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==","datePublished":"2025-03-25T12:08:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDAzNSM2ODMxOTgyIzUwMDExMzcwMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829380"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829380\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}